Abstract
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Diabetic Medicine |
| Vol/bind | 10 |
| Udgave nummer | 11 |
| Sider (fra-til) | 994-1003 |
| Antal sider | 9 |
| ISSN | 0742-3071 |
| DOI | |
| Status | Udgivet - 2008 |
Adgang til dokumentet
Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
GLP-1: physiological effects and potential therapeutic applications. / Aaboe, Kasper; Krarup, Thure; Madsbad, Sten; Holst, Jens Juul; Aaboe, Kasper; Krarup, Thure; Madsbad, Sten; Holst, Jens Juul.
I: Diabetic Medicine, Bind 10, Nr. 11, 2008, s. 994-1003.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
}
TY - JOUR
T1 - GLP-1: physiological effects and potential therapeutic applications
AU - Aaboe, Kasper
AU - Krarup, Thure
AU - Madsbad, Sten
AU - Holst, Jens Juul
AU - Aaboe, Kasper
AU - Krarup, Thure
AU - Madsbad, Sten
AU - Holst, Jens Juul
PY - 2008
Y1 - 2008
N2 - Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone with the potential to change diabetes. The physiological effects of GLP-1 are multiple, and many seem to ameliorate the different conditions defining the diverse physiopathology seen in type 2 diabetes. In animal studies, GLP-1 stimulates beta-cell proliferation and neogenesis and inhibits beta-cell apoptosis. In humans, GLP-1 stimulates insulin secretion and inhibits glucagon and gastrointestinal secretions and motility. It enhances satiety and reduces food intake and has beneficial effects on cardiovascular function and endothelial dysfunction. Enhancing incretin action for therapeutic use includes GLP-1 receptor agonists resistant to degradation (incretin mimetics) and dipeptidyl peptidase (DPP)-4 inhibitors. In clinical trials with type 2 diabetic patients on various oral antidiabetic regimes, both treatment modalities efficaciously improve glycaemic control and beta-cell function. Whereas the incretin mimetics induce weight loss, the DPP-4 inhibitors are considered weight neutral. In type 1 diabetes, treatment with GLP-1 shows promising effects. However, several areas need clinical confirmation: the durability of the weight loss, the ability to preserve functional beta-cell mass and the applicability in other than type 2 diabetes. As such, long-term studies and studies with cardiovascular end-points are needed to confirm the true benefits of these new classes of antidiabetic drugs in the treatment of diabetes mellitus.
AB - Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone with the potential to change diabetes. The physiological effects of GLP-1 are multiple, and many seem to ameliorate the different conditions defining the diverse physiopathology seen in type 2 diabetes. In animal studies, GLP-1 stimulates beta-cell proliferation and neogenesis and inhibits beta-cell apoptosis. In humans, GLP-1 stimulates insulin secretion and inhibits glucagon and gastrointestinal secretions and motility. It enhances satiety and reduces food intake and has beneficial effects on cardiovascular function and endothelial dysfunction. Enhancing incretin action for therapeutic use includes GLP-1 receptor agonists resistant to degradation (incretin mimetics) and dipeptidyl peptidase (DPP)-4 inhibitors. In clinical trials with type 2 diabetic patients on various oral antidiabetic regimes, both treatment modalities efficaciously improve glycaemic control and beta-cell function. Whereas the incretin mimetics induce weight loss, the DPP-4 inhibitors are considered weight neutral. In type 1 diabetes, treatment with GLP-1 shows promising effects. However, several areas need clinical confirmation: the durability of the weight loss, the ability to preserve functional beta-cell mass and the applicability in other than type 2 diabetes. As such, long-term studies and studies with cardiovascular end-points are needed to confirm the true benefits of these new classes of antidiabetic drugs in the treatment of diabetes mellitus.
U2 - 10.1111/j.1463-1326.2008.00853.x
DO - 10.1111/j.1463-1326.2008.00853.x
M3 - Journal article
C2 - 18435775
VL - 10
SP - 994
EP - 1003
JO - Diabetic Medicine
JF - Diabetic Medicine
SN - 0742-3071
IS - 11
ER -